Four separate lawsuits are now moving through the courts against the two largest makers of GLP-1 drugs, Novo Nordisk and Eli Lilly, all centered on how these medications are priced and marketed. A fifth development, an FDA label change for Zepbound announced without explanation, adds another layer of uncertainty. For patients who rely on these drugs or are considering starting one, these cases could shape what you pay and what you're told about the medication in the months ahead.
The case, Schultze v. Novo Nordisk Inc., centers on how the company prices and markets its GLP-1 drugs, and the court's eventual ruling could directly affect what patients pay at the pharmacy counter. Because the lawsuit is still working through the legal process, no final decision has been reached, and the specific arguments Novo Nordisk will make in its defense are not yet part of the public record. Patients currently paying out of pocket for GLP-1 medications, or watching their insurance coverage change, have a direct stake in how this case unfolds. I would suggest following the case record linked above if pricing is a concern for you, since any ruling here could set a precedent that reaches beyond this single lawsuit.
A second, separate lawsuit, Urbina-Ramos v. Novo Nordisk Inc., raises similar concerns about the company's marketing and pricing practices, but the specific claims in the complaint have not yet been made public. That the case exists at all signals that legal challenges to Novo Nordisk's pricing practices are not limited to a single plaintiff or a single legal theory. Multiple cases moving forward at once can sometimes indicate a broader pattern of concern among consumers or regulators, though it is too early to say what connects the claims in this filing to those in the others. Readers should treat this case as a separate track, since its outcome will not necessarily mirror what happens in the other pending suits.
A third case, Garrett v. Novo Nordisk A/S, adds to the number of active challenges against the company by accusing it of unfair pricing practices tied to its GLP-1 products. The details of the complaint remain sealed, so it is not yet possible to say exactly what pricing decisions or marketing statements are being disputed. With three separate lawsuits now naming Novo Nordisk over similar issues, patients and industry observers alike may want to watch whether the courts eventually consolidate these cases or allow them to proceed independently. Either path could change how quickly answers become available to the public.
The fourth lawsuit, Reed v. Eli Lilly and Company, moves the legal scrutiny beyond Novo Nordisk and into federal court against Eli Lilly, the other major manufacturer of GLP-1 drugs. This case similarly challenges the company's pricing and marketing practices, though the full claims have not yet been disclosed. Because this suit is filed in federal court rather than state court, its outcome could carry broader weight and potentially influence how GLP-1 pricing is regulated across state lines. Patients who use Eli Lilly's GLP-1 products, including those prescribed for weight management or diabetes, may want to pay particular attention to how this case develops, given that the company is now facing the same kind of legal pressure that Novo Nordisk faces on three fronts.
Separate from the courtroom activity, the FDA approved a label change for Zepbound on August 26, 2026, under supplement 41 to its original approval, NDA217806. The agency has not yet released what the label change actually says, which leaves open questions about whether it affects dosing, warnings, approved uses, or something else entirely. Label changes can carry real consequences for patients, since they sometimes reflect new safety information or expand who the drug can be prescribed to. Until the FDA publishes the specifics, patients currently taking Zepbound may want to check with their prescriber periodically for updates, rather than assume the change has no bearing on their treatment.
None of these five developments have reached a resolution yet, which means there is no immediate action required for most patients. Still, the number of active legal challenges against both Novo Nordisk and Eli Lilly suggests that questions about GLP-1 pricing are becoming harder for the industry to avoid. If you take a GLP-1 medication, I would suggest checking back on these case records periodically, particularly if you are budgeting for ongoing treatment costs or considering starting a new prescription. Two things are worth keeping in mind: the outcomes of these lawsuits could eventually change what patients pay, and the FDA's unexplained label change may carry its own implications once the details are released.
Key details
A pending lawsuit against Novo Nordisk could affect how much patients pay for GLP-1 drugs.
Another case against Novo Nordisk is pending, though its claims remain undisclosed.
A third lawsuit accuses Novo Nordisk of unfair GLP-1 pricing, with details still sealed.
Eli Lilly now faces a federal lawsuit over its GLP-1 pricing and marketing practices.
The FDA approved a Zepbound label change on August 26, 2026, but details remain unclear.
Read this on GLP1Laws: https://glp1laws.com/patient-lens/access-roundup-2026-08-25